Brian I Rini

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Immunotherapy for prostate cancer
    B I Rini
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisidero Street, 3rd Floor, San Francisco, CA 94115, USA
    Curr Oncol Rep 3:418-23. 2001
  2. ncbi New approaches in advanced renal cell carcinoma
    Brian I Rini
    Department of Medicine, UCSF Comprehensive Cancer Center, San Francisco, CA, USA
    Urol Oncol 23:65-6. 2005
  3. ncbi VEGF-targeted therapy in metastatic renal cell carcinoma
    Brian I Rini
    1600 Divisadero, Room A717, San Francisco, California 94115, USA
    Oncologist 10:191-7. 2005
  4. ncbi A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma
    Brian I Rini
    Department of Hematology Oncology, The University of California San Francisco Comprehensive Cancer Center, San Francisco, California, USA
    Cancer 103:553-8. 2005
  5. ncbi Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma
    Brian I Rini
    University of California San Francisco Comprehensive Cancer Center, CA, USA
    J Clin Oncol 23:1028-43. 2005
  6. ncbi Recent clinical development of dendritic cell-based immunotherapy for prostate cancer
    Brian Rini
    UCSF Comprehensive Cancer Center, 1600 Divisidero, 3rd Floor, San Francisco, CA 94115, USA
    Expert Opin Biol Ther 4:1729-34. 2004
  7. ncbi Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma
    Brian I Rini
    UCSF Comprehensive Cancer Center, The University of California San Francisco, 1600 Divisadero, Rm A717, San Francisco, CA 94115, USA
    Cancer 101:90-5. 2004
  8. ncbi Practice and progress in kidney cancer: methodology for novel drug development
    Brian I Rini
    Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94115, USA
    J Urol 171:2115-21. 2004
  9. ncbi Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma
    Brian I Rini
    University of California at San Francisco, San Francisco, California 94115, USA
    Clin Cancer Res 10:2584-6. 2004
  10. ncbi The potential for prostate cancer immunotherapy
    Brian I Rini
    University of California San Francisco UCSF Comprehensive Cancer Center, USA
    Crit Rev Oncol Hematol 46:S117-25. 2003

Detail Information

Publications73

  1. ncbi Immunotherapy for prostate cancer
    B I Rini
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisidero Street, 3rd Floor, San Francisco, CA 94115, USA
    Curr Oncol Rep 3:418-23. 2001
    ..Many approaches in prostate cancer have demonstrated successful induction of the desired immune response. Limited clinical success has also been seen...
  2. ncbi New approaches in advanced renal cell carcinoma
    Brian I Rini
    Department of Medicine, UCSF Comprehensive Cancer Center, San Francisco, CA, USA
    Urol Oncol 23:65-6. 2005
  3. ncbi VEGF-targeted therapy in metastatic renal cell carcinoma
    Brian I Rini
    1600 Divisadero, Room A717, San Francisco, California 94115, USA
    Oncologist 10:191-7. 2005
    ..To review the biology of renal cell carcinoma (RCC) and the clinical results of vascular endothelial growth factor (VEGF) blockade in metastatic RCC...
  4. ncbi A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma
    Brian I Rini
    Department of Hematology Oncology, The University of California San Francisco Comprehensive Cancer Center, San Francisco, California, USA
    Cancer 103:553-8. 2005
    ..Fixed dose rate gemcitabine infusion leads to enhanced intracellular accumulation of drug and possible augmented clinical effect. To determine the toxicity of this combination therapy in metastatic RCC, a Phase I trial was conducted...
  5. ncbi Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma
    Brian I Rini
    University of California San Francisco Comprehensive Cancer Center, CA, USA
    J Clin Oncol 23:1028-43. 2005
    ..To review the biology of renal cell carcinoma (RCC) leading to vascular endothelial growth factor (VEGF) overexpression and the clinical results of VEGF blockade in metastatic RCC...
  6. ncbi Recent clinical development of dendritic cell-based immunotherapy for prostate cancer
    Brian Rini
    UCSF Comprehensive Cancer Center, 1600 Divisidero, 3rd Floor, San Francisco, CA 94115, USA
    Expert Opin Biol Ther 4:1729-34. 2004
    ..Many approaches in prostate cancer have demonstrated successful induction of the desired immune response. Clinical effect has also been observed, prompting larger definitive trials...
  7. ncbi Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma
    Brian I Rini
    UCSF Comprehensive Cancer Center, The University of California San Francisco, 1600 Divisadero, Rm A717, San Francisco, CA 94115, USA
    Cancer 101:90-5. 2004
    ..Given the historically low objective response rate in RCC, time to disease progression (TTP) as an alternative endpoint was employed to evaluate the antitumor activity of UCN-01 in RCC...
  8. ncbi Practice and progress in kidney cancer: methodology for novel drug development
    Brian I Rini
    Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94115, USA
    J Urol 171:2115-21. 2004
    ..Furthermore, we describe new paradigms for the evaluation of novel agents to optimize the yield of clinical research in RCC...
  9. ncbi Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma
    Brian I Rini
    University of California at San Francisco, San Francisco, California 94115, USA
    Clin Cancer Res 10:2584-6. 2004
    ..A Phase III trial is now being conducted randomizing untreated, metastatic clear cell RCC patients to IFN-alpha alone or IFN-alpha plus Avastin...
  10. ncbi The potential for prostate cancer immunotherapy
    Brian I Rini
    University of California San Francisco UCSF Comprehensive Cancer Center, USA
    Crit Rev Oncol Hematol 46:S117-25. 2003
    ..Many approaches in prostate cancer have demonstrated successful induction of the desired immune response. Limited clinical success has also been seen...
  11. ncbi Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer
    Brian I Rini
    University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA
    J Clin Oncol 21:99-105. 2003
    ....
  12. ncbi Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results
    Brian I Rini
    University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115, USA
    J Clin Oncol 20:2017-24. 2002
    ..To evaluate the feasibility and safety of nonmyeloablative allogeneic stem-cell transplantation in patients with metastatic renal cell cancer (RCC) and to evaluate efficacy with respect to engraftment and tumor regression...
  13. ncbi Hormone-refractory Prostate Cancer
    Brian I Rini
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Avenue, 3rd Floor, 94115, USA
    Curr Treat Options Oncol 3:437-46. 2002
    ..Furthermore, the application of chemotherapeutic regimens has provided viable treatment options for patients with HRPC...
  14. doi Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
    Juan Barbastefano
    Department of Medicine, Cleveland Clinic, Cleveland, OH, USA
    BJU Int 106:1266-9. 2010
    ....
  15. ncbi A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 5:323-8. 2007
    ..Imatinib inhibits the platelet-derived growth factor receptor that is expressed in prostate cancer and is synergistic with taxanes in preclinical prostate cancer models...
  16. ncbi A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Clin Cancer Res 13:1810-5. 2007
    ....
  17. doi Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF
    Lawrence Fong
    Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Res 69:609-15. 2009
    ....
  18. ncbi Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status
    Brian I Rini
    Department of Medicine, The University of California San Francisco, San Francisco, California, USA
    BJU Int 98:756-62. 2006
    ..To describe the relationship among patient characteristics, Von Hippel-Lindau (VHL) gene status and clinical outcome in metastatic renal cell carcinoma (RCC) in patients receiving vascular endothelial growth factor (VEGF)-targeted therapy...
  19. ncbi Sunitinib in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    JAMA 295:2516-24. 2006
    ..Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, which has shown activity in an initial study of cytokine-refractory metastatic RCC patients...
  20. pmc Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
    Samuel E DePrimo
    Translational Medicine, Pfizer Global Research and Development, La Jolla, CA, USA
    J Transl Med 5:32. 2007
    ....
  21. ncbi Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Room A 718, San Francisco, CA 94115, USA
    J Clin Oncol 22:1025-33. 2004
    ..Thereafter, adrenal androgen ablation with agents such as ketoconazole (K) is commonly utilized. The therapeutic effect of AAWD alone was compared with simultaneous AAWD and K therapy...
  22. ncbi Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study
    Brian I Rini
    Department of Medicine, University of California San Francisco Cancer Center, San Francisco, California, USA
    Biol Blood Marrow Transplant 12:778-85. 2006
    ..A graft-versus-tumor effect was not observed in this study despite acute and chronic GVHD, thus highlighting the need for further understanding of this approach. Allogeneic SCT remains investigational in RCC...
  23. doi The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer
    David Knight
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA
    Prostate 69:142-8. 2009
    ..One vaccination strategy that is being pursued in the clinic utilizes peptide-pulsed peripheral blood mononuclear cells (PBMC) + IL-12...
  24. ncbi A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma
    Apurva A Desai
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Cancer 95:1629-36. 2002
    ....
  25. ncbi A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy
    Amy M Lin
    University of California San Francisco, San Francisco, CA 94115, USA
    BJU Int 98:763-9. 2006
    ..East Hanover, NJ, USA), as measured by prostate-specific antigen (PSA) kinetics in men with biochemical relapse of prostate cancer after definitive local therapy...
  26. ncbi Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer
    Garth Beinart
    Department of Hematology Oncology, M D Anderson Cancer Center, USA
    Clin Prostate Cancer 4:55-60. 2005
    ..This phase II trial was conducted to assess the prostate-specific antigen (PSA)-modulating effects of APC8015 in patients with androgen-dependent prostate cancer (ADPC) with biochemical progression...
  27. pmc Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma
    Saby George
    Division of Hematology and Oncology, Department of Medicine, The University of Texas Health Science Center, San Antonio, TX 78229, USA
    Clin Genitourin Cancer 6:79-85. 2008
    ..In vitro experiments demonstrated that suramin, at noncytotoxic doses, enhanced the activity of chemotherapy including 5-fluorouracil (5-FU) in xenograft models...
  28. ncbi Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor
    Brian I Rini
    University of California San Francisco Comprehensive Cancer Center, San Francisco, California, USA
    J Urol 175:2087-91. 2006
    ..We describe the clinical and immunological characteristics of patients with biochemically relapsed prostate cancer who achieved long-term disease control with GM-CSF (Leukine)...
  29. ncbi Prostate cancer update
    Brian I Rini
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94115, USA
    Curr Opin Oncol 14:286-91. 2002
    ..This article reviews the major advances in prostate cancer published between November 1, 2000, and October 31, 2001...
  30. ncbi Technology evaluation: APC-8015, Dendreon
    Brian I Rini
    UCSF Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Curr Opin Mol Ther 4:76-9. 2002
    ..In April 2001, Dendreon was awarded US-06210662 covering the therapeutic composition of APC-8015 [406383]...
  31. ncbi Clinical trials in patients with biochemically relapsed prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    BJU Int 97:905-10. 2006
    ..Finally there are two papers from Australia describing the use of positron emission tomography in renal cancer and in prostate cancer...
  32. ncbi Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:16-24. 2006
    ..SU11248 (sunitinib malate), a small molecule inhibitor with high binding affinity for VEGF and PDGF receptors, was tested for clinical activity in patients with metastatic RCC...
  33. ncbi Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma
    Manuel S Eisenberg
    Department of Urology, University of California San Francisco, San Francisco, California 94143 1695, USA
    J Endourol 20:504-8. 2006
    ..We compared the outcomes of patients with metastatic RCC undergoing laparoscopic and open cytoreductive nephrectomy prior to systemic therapy...
  34. doi Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study
    Lauren C Harshman
    Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
    Lancet Oncol 13:927-35. 2012
    ..We assessed the use of conditional survival--a measure that accounts for elapsed time since treatment initiation--for prognostication in patients with metastatic renal-cell carcinoma treated with first-line VEGF-targeted therapies...
  35. ncbi Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 107:67-74. 2006
    ..A clinical trial was conducted to determine the prostate-specific antigen (PSA) and immunomodulatory effects of this combination immunotherapy...
  36. ncbi The role of targeted therapy in metastatic renal cell carcinoma
    Jaya Unnithan
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
    ScientificWorldJournal 7:800-7. 2007
    ..This article briefly describes the biological pathways involved in the development of RCC and the results of clinical trials using targeted therapy in metastatic RCC...
  37. ncbi Molecularly targeted therapy in renal cell carcinoma
    W Kimryn Rathmell
    Lineberger Comprehensive Cancer Center, University of North Carolina, Campus Box 7295, Chapel Hill, NC 27599 7295, USA
    Expert Rev Anticancer Ther 5:1031-40. 2005
    ..However, investigation is needed to optimally utilize these agents at the appropriate stage of disease and in the best combinations for maximal clinical benefit...
  38. ncbi Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
    Olivier Rixe
    Pitie Salpetriere Hospital, University of Paris, Paris, France
    Lancet Oncol 8:975-84. 2007
    ..We aimed to assess the activity and safety of axitinib in patients with metastatic renal-cell cancer who had failed on previous cytokine-based treatment...
  39. ncbi Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy
    Ila Tamaskar
    Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Urol 179:81-6; discussion 86. 2008
    ..Currently, several agents with a putative antiangiogenic mechanism exist and they are often being used in sequence with little to no data regarding activity in a second line or later setting...
  40. doi Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 26:127-31. 2008
    ..The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated...
  41. ncbi Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma
    Daniel Y C Heng
    Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    Clin Genitourin Cancer 5:446-51. 2007
    ..Additionally, nCRs can be seen despite nonpulmonary metastatic sites and previous VEGF-targeted therapy...
  42. doi Renal cell carcinoma
    Brian I Rini
    Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
    Curr Opin Oncol 20:300-6. 2008
    ..This study is intended to update prognostic and therapeutic decision-making data and provide perspective on advances in understanding the molecular biology of this disease...
  43. ncbi Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress?
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological and Kidney Institute, Cleveland, Ohio 44195, USA
    Oncology (Williston Park) 22:388-96; discussion 396, 402-3, 476 passim. 2008
    ..Novel agents targeting the VEGF or alternative pathways have also emerged and are beginning to undergo clinical testing...
  44. ncbi VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices
    Brian I Rini
    Cleveland Clinic Foundation, 9500 Euclid Avenue Desk R35, Cleveland, OH 44195, USA
    Curr Oncol Rep 8:85-9. 2006
    ..The biology, clinical results, and future considerations regarding VEGF-targeted agents in RCC are presented in this article...
  45. doi von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Urol 180:860-5; discussion 865-6. 2008
    ..The von Hippel-Lindau (VHL) gene is often inactivated (by mutation or promoter hypermethylation) in renal cell carcinoma but the relation to therapeutic outcome is unclear...
  46. doi Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 26:3743-8. 2008
    ..To assess the safety and efficacy of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib response...
  47. doi Targeted therapy in renal cell carcinoma
    Bhanu K Vakkalanka
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Curr Opin Urol 18:481-7. 2008
    ..A better understanding of renal cell carcinoma biology has led to a new era of targeted therapy in the management of metastatic renal cell carcinoma...
  48. doi Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Urol Oncol 26:543-9. 2008
    ..Several relevant clinical aspects have also emerged with use of these agents such as defining resistance, measurement of response, and combination therapy...
  49. ncbi Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development
    Brian I Rini
    Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    BJU Int 96:286-90. 2005
  50. ncbi Renal cell carcinoma
    W Kimryn Rathmell
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599 7295, USA
    Curr Opin Oncol 17:261-7. 2005
    ..Given historically limited advances in this disease, a more thorough understanding and testing of rationally targeted agents is needed...
  51. ncbi Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 22:3705-12. 2004
    ..To evaluate the herbal combination, PC-SPES, and diethylstilbestrol (DES) in patients with androgen independent prostate cancer (AIPC)...
  52. ncbi Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity
    Brian I Rini
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, U S A
    J Immunother 25:269-77. 2002
    ....
  53. ncbi Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma
    Brian I Rini
    Department of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 106:566-75. 2006
    ..Based on potential additive or synergistic antitumor effects, interferon-alpha (IFNalpha) and celecoxib, an oral COX-2 inhibitor, were given to metastatic RCC patients in a Phase II trial...
  54. ncbi Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
    Toni K Choueiri
    Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
    Cancer 110:543-50. 2007
    ..The identification of patients who are more likely to benefit from these agents is warranted...
  55. ncbi What is standard initial systemic therapy in metastatic renal cell carcinoma?
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, OH 44195, USA
    Clin Genitourin Cancer 5:256-63. 2007
    ..As new standard therapies for metastatic RCC emerge, clinical trial conduct remains a priority to further optimize patient outcome...
  56. ncbi Renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
    Curr Opin Oncol 18:289-96. 2006
    ..In addition, this review will update recent advances in diagnostic and imaging modalities for renal cell carcinoma and dietary and environmental relationships to the epidemiology of this growing disease...
  57. ncbi Sorafenib
    Brian I Rini
    Department of Solid Tumour Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Expert Opin Pharmacother 7:453-61. 2006
    ..Sorafenib is well tolerated, with common toxicities including rash, diarrhoea, hand-foot skin reaction, fatigue and hypertension, when administered as the standard dose of 400 mg b.i.d...
  58. ncbi Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports
    Philip E Shaheen
    Experimental Therapeutics Program, Taussig Cancer Center, Cleveland Clinic, OH 44195, USA
    Clin Genitourin Cancer 5:78-81. 2006
    ..We report 2 cases highlighting that efficacy of these agents is possible after failure of the other agent. Further prospective study is needed...
  59. ncbi Current status and future directions of molecular markers in renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Curr Opin Urol 16:332-6. 2006
    ..To describe the existing data regarding the prognostic and/or predictive value of molecular markers in metastatic renal cell carcinoma...
  60. ncbi Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma
    G Kesava Reddy
    CIG Media Group, LP, Dallas, TX, USA
    Clin Genitourin Cancer 5:110-3. 2006
    ..However, optimal dose, treatment schedule, selection of patients, and appropriate combination strategies with other novel agents need to be defined for mTOR-targeted therapies in the treatment of advanced-stage RCC...
  61. ncbi The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma
    Toni K Choueiri
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    Semin Oncol 33:596-606. 2006
    ..This review will describe the current clinical data with VEGF-targeted approaches in RCC and plans for future development...
  62. ncbi Phase II study of lenalidomide in patients with metastatic renal cell carcinoma
    Toni K Choueiri
    Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
    Cancer 107:2609-16. 2006
    ..A Phase II, open-label study of LEN in patients with metastatic renal cell carcinoma (RCC) was conducted to determine its safety and clinical activity...
  63. ncbi Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
    Brian I Rini
    Cleveland Clinic Taussig Cancer Center, Department of Solid Tumor Oncology and Urology, 9500 Euclid Avenue Desk R35, Cleveland, OH 44195, USA
    Expert Rev Anticancer Ther 6:1753-60. 2006
    ..These issues are discussed in light of current data and strategies for further drug development are presented...
  64. ncbi Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
    Brian I Rini
    Department of Solid Tumor Oncology, Taussig Cancer Center, Cleveland Clinic, 9500 Euclid Ave, Desk R35, Cleveland, OH 44195, USA
    J Natl Cancer Inst 99:81-3. 2007
    ..Thyroid function test abnormalities appear to be common in patients with metastatic renal cell carcinoma treated with sunitinib, and routine monitoring is warranted...
  65. ncbi Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, OH 44195, USA
    Clin Genitourin Cancer 5:232-4. 2006
    ..Herein, we report 2 cases of patients with cytokine-refractory metastatic RCC who received sunitinib and achieved sufficient decrease in tumor burden to permit subsequent surgical resection, resulting in long-term CR...
  66. ncbi Therapeutic considerations in patients with metastatic renal cell carcinoma previously treated with antiangiogenic therapies
    Saby George
    Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    Clin Genitourin Cancer 5:S40-4. 2006
    ..This review will examine the existing data in this setting, describe ongoing clinical investigations, and discuss challenges unique to this patient population...
  67. ncbi Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Clin Cancer Res 13:741s-746s. 2007
    ..VEGF-Trap is also a VEGF binding molecule with ongoing investigation in RCC...
  68. ncbi Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Clin Cancer Res 13:1098-106. 2007
    ..This article also reviews future development strategies, including combination regimens and drug sequencing, trial design considerations, and patient selection opportunities...
  69. ncbi SU11248 and AG013736: current data and future trials in renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
    Clin Genitourin Cancer 4:175-80. 2005
    ..Substantial clinical activity has been reported for these agents in metastatic RCC trials, leading to additional investigations in a variety of settings...
  70. ncbi Recent progress in the management of advanced renal cell carcinoma
    Jorge A Garcia
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, OH, USA
    CA Cancer J Clin 57:112-25. 2007
    ..This generation of novel molecular targeted therapies continues to show great promise. The purpose of this review is to summarize the current management and to discuss potential future directions in the management of metastatic RCC...
  71. ncbi Immunotherapy for metastatic renal cell carcinoma
    David F McDermott
    DF HCC Renal Cancer Program, Beth Israel Deaconess Medical Center, Boston, MA, USA
    BJU Int 99:1282-8. 2007
  72. ncbi The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center and Section of Urological Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Urol 177:1978-84. 2007
    ..Accomplishing this in the current era of targeted molecular therapies presents unique challenges and opportunities...
  73. doi Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities
    Donna E Hansel
    Department of Anatomic Pathology, Glickman Urological and Kidney Institute and Taussig Cancer Institute, The Cleveland Clinic, 9500 Euclid Avenue, Desk L25, Cleveland, OH 44195, USA
    Expert Rev Anticancer Ther 8:895-905. 2008
    ....